Levetiracetam Injection
Product Images NDC 66298-0427

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 66298-0427). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hp Halden Pharma As, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Label)

A data table comparing the percentage of various adverse reactions reported for Levetiracetam (N=769) and placebo (N=439). The table lists adverse reactions such as asthenia, somnolence, headache, infection, dizziness, and others, with corresponding percentages for each group.*

FDA Label Image

Label03 (Label03)

A bar chart showing the percentage of patients by treatment group relating to Levetiracetam injection. The groups include placebo (6.3%, N=111), Levetiracetam 1,000 mg/day (20.8%, N=106), and Levetiracetam 2,000 mg/day (35.2%, N=105). The chart denotes a statistically significant difference versus placebo for the Levetiracetam groups.*

FDA Label Image

Label04 (Label04)

A bar chart comparing the percentage of patients between two groups: Placebo (N=104) and Levetiracetam 3,000 mg/day (N=180). The vertical axis represents the percentage of patients, with the Placebo group at 14.4% and the Levetiracetam group at 39.4%, marked with an asterisk indicating statistical significance versus placebo.*

FDA Label Image

Label05 (Label05)

Bar chart comparing the percentage of patients between placebo and levetiracetam groups. The placebo group (N=84) shows 45.2% of patients, while the levetiracetam group (N=79) shows 72.2%, with a notation indicating statistical significance versus placebo.*

FDA Label Image

Label06 (Label06)

FDA Label Image

Label07 (Label07)

Label for Levetiracetam 5 mg/mL injection in 0.82% Sodium Chloride Injection. The product is packaged as 24 single-dose 100 mL bags, each containing 500 mg of Levetiracetam. Manufactured for Fresenius Kabi, Lake Zurich, IL, made in Norway. The label includes storage instructions, batch lot, expiration date placeholders, and barcodes.*

FDA Label Image

Label08 (Label08)

This image shows the drug facts panel for Levetiracetam injection in 0.82% Sodium Chloride, 500 mg in 100 mL (5 mg/mL). It includes instructions for intravenous infusion only, storage conditions (20° to 25°C), composition details, and cautionary statements. The panel notes the product is for single-dose use, manufactured for Fresenius Kabi, and made in Norway.*

FDA Label Image

Label09 (Label09)

Label for Levetiracetam injection in 0.82% sodium chloride, 500 mg in 100 mL (5 mg/mL) intravenous infusion. The label specifies use for intravenous infusion only and indicates prescription-only status. Includes a QR code and batch identification numbers.*

FDA Label Image

Label2 (Label2)

A bar chart showing the percentage of patients experiencing an outcome across three groups: Placebo (7.4%, N=95), Levetiracetam 1,000 mg/day (37.1%, N=97), and Levetiracetam 3,000 mg/day (39.6%, N=101). The chart includes a note indicating the results for both Levetiracetam groups are statistically significant compared to placebo.*

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical structure of levetiracetam. The diagram shows the molecular arrangement characteristic of levetiracetam with labeled chemical groups including a pyrrolidone ring and side chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.